PMC:7408073 / 69965-70862
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T423 | 644-651 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 2473 | 53-57 | Gene | denotes | ACE2 | Gene:59272 |
| 2474 | 264-268 | Gene | denotes | ACE2 | Gene:59272 |
| 2475 | 371-375 | Gene | denotes | ACE2 | Gene:59272 |
| 2476 | 510-514 | Gene | denotes | ACE2 | Gene:59272 |
| 2477 | 638-643 | Gene | denotes | hACE2 | Gene:59272 |
| 2478 | 221-231 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 2479 | 365-370 | Species | denotes | human | Tax:9606 |
| 2480 | 731-739 | Species | denotes | patients | Tax:9606 |
| 2481 | 769-775 | Chemical | denotes | rhACE2 | |
| 2482 | 101-119 | Disease | denotes | SARS-CoV infection | MESH:C000657245 |
| 2483 | 298-313 | Disease | denotes | viral infection | MESH:D001102 |
| 2484 | 406-414 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 2485 | 428-432 | Disease | denotes | ARDS | MESH:D012128 |
| 2486 | 722-730 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 2487 | 779-783 | Disease | denotes | ARDS | MESH:D012128 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T334 | 101-119 | Disease | denotes | SARS-CoV infection | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T335 | 101-105 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T336 | 110-119 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T337 | 221-229 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T338 | 221-225 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T339 | 298-313 | Disease | denotes | viral infection | http://purl.obolibrary.org/obo/MONDO_0005108 |
| T340 | 304-313 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T341 | 406-414 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T342 | 428-432 | Disease | denotes | ARDS | http://purl.obolibrary.org/obo/MONDO_0006502 |
| T343 | 437-440 | Disease | denotes | PAH | http://purl.obolibrary.org/obo/MONDO_0015924 |
| T344 | 722-730 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T345 | 779-783 | Disease | denotes | ARDS | http://purl.obolibrary.org/obo/MONDO_0006502 |
| T346 | 788-791 | Disease | denotes | PAH | http://purl.obolibrary.org/obo/MONDO_0015924 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T871 | 318-319 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T872 | 343-344 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T873 | 365-370 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
| T874 | 376-379 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T875 | 495-501 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | active |
| T876 | 603-604 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T877 | 652-655 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T878 | 812-816 | http://purl.obolibrary.org/obo/CLO_0001185 | denotes | 2018 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T45243 | 87-97 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T93394 | 437-440 | Chemical | denotes | PAH | http://purl.obolibrary.org/obo/CHEBI_104011|http://purl.obolibrary.org/obo/CHEBI_31204|http://purl.obolibrary.org/obo/CHEBI_33848|http://purl.obolibrary.org/obo/CHEBI_53305 |
| T26208 | 644-651 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
| T274 | 788-791 | Chemical | denotes | PAH | http://purl.obolibrary.org/obo/CHEBI_104011|http://purl.obolibrary.org/obo/CHEBI_31204|http://purl.obolibrary.org/obo/CHEBI_33848|http://purl.obolibrary.org/obo/CHEBI_53305 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T141 | 298-313 | http://purl.obolibrary.org/obo/GO_0016032 | denotes | viral infection |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T344 | 0-137 | Sentence | denotes | Finally, soluble and catalytically inactive forms of ACE2 have been shown to be potent inhibitors of SARS-CoV infection products [19,21]. |
| T345 | 138-238 | Sentence | denotes | An approach that could be pursued (in combination with other therapies) to inhibit SARS-CoV-2 entry. |
| T346 | 239-455 | Sentence | denotes | Indeed, soluble forms of ACE2 are expected to protect from viral infection and a similar strategy using a recombinant form of human ACE2 has been proposed not only in COVID-19, but also in ARDS and PAH [108,133,134]. |
| T347 | 456-586 | Sentence | denotes | However, it is possible that catalytic active form of ACE2 might favour adverse effects in these specific pathological conditions. |
| T348 | 587-897 | Sentence | denotes | To this regard, a clinical trial using recombinant hACE2 protein has been recently started (ClinicalTrials.gov number, NCT04287686) in COVID-19 patients and pilot clinical trials of rhACE2 in ARDS and PAH started in 2017 and 2018, respectively [108,134]; unfortunately, no conclusive results are available yet. |
2_test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 32708755-15367630-20678891 | 130-132 | 15367630 | denotes | 19 |
| 32708755-16510163-20678892 | 133-135 | 16510163 | denotes | 21 |
| 32708755-29903860-20678893 | 442-445 | 29903860 | denotes | 108 |
| 32708755-32333836-20678894 | 446-449 | 32333836 | denotes | 133 |
| 32708755-28877748-20678895 | 450-453 | 28877748 | denotes | 134 |
| 32708755-29903860-20678896 | 832-835 | 29903860 | denotes | 108 |
| 32708755-28877748-20678897 | 836-839 | 28877748 | denotes | 134 |